Method for identifying and quantifying of tumuor-associated

Details Method for identifying and quantifying of tumuor-associated Method for identifying and quantifying of tumuor-associated

2005-01-28

2010-10-12

Yu, Misook (Department: 1642)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C435S007100, C436S064000, C436S504000, C436S544000, C436S545000

Reexamination Certificate

active

07811828

ABSTRACT:
Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.

REFERENCES:
patent: 2005/0239209 (2005-10-01), Krakover
patent: 2008/0207497 (2008-08-01), Ramakrishna
patent: 02046416 (2002-06-01), None
patent: 03025576 (2003-03-01), None
patent: WO 03/025576 (2003-03-01), None
patent: 2007150077 (2007-12-01), None
patent: 2008070047 (2008-06-01), None
patent: 2008088583 (2008-07-01), None
patent: 2009036246 (2009-03-01), None
Beardsley et al., “Optimization of Guanidination Procedures for MALDI Mass Mapping,”Anal. Chem., Apr. 15, 2002, pp. 1884-1890, vol. 74, No. 8.
Lemmel et al., “Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling,”Nature Biotechnology, Apr. 2004, pp. 450-454, vol. 22, No. 4.
Martin et al., “Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium,”Cancer Research, Jan. 1, 2004, pp. 347-355, vol. 64, No. 1.
Moritz et al., “Approaches for the quantification of protein concentration ratios,”Proteomics, Nov. 2003, pp. 2208-2220, vol. 3, No. 11.
Weinschenk et al., “Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines,”Cancer Research, Oct. 15, 2002, pp. 5818-5827, vol. 62, No. 20.
Phillip, R. et al. “Shared Immunoproteome for ovarian cancer diagnostics and immunotherapy: Potential theranostic approach to cancer,” J. Proteome Res. 2007;6(7):2509-2517.
Moritz B. et al. “Approaches for the Quantification of Protein Concentration Ratios”, Proteomics, vol. 3, No. 11, Nov. 2003, pp. 2208-2220, XP002359083 ISSN: 1615-9853.
Weinshenk T. et al.: “Integrated Functional Genomics Approach for the Design of Patient-Individual Antitumor Vaccines”, Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 62, No. 20, Oct. 15, 2002, pp. 5818-5827, XP002266492 ISSN: 0008-5472.
Beardsley R. “Optimization of Guanidination Procedures for MALDI Mass Mapping”, Analytical Chemistry, Apr. 15, 2002, vol. 74, No. 8, pp. 1884-1890, XP002359084 ISSN:0003-27000.
Lemmel C. et al. “Differential Quantitative Analysis of MHC Ligands by Mass Spectrometry Using Stable Isotope Labeling”, Nature Biotechnology, vol. 22, No. 4, Apr. 2004, pp. 450-454, XP002359085 ISSN: 1087-0156.

Affiliated with

Also associated with

Rating

Method for identifying and quantifying of tumuor-associated does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for identifying and quantifying of tumuor-associated, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying and quantifying of tumuor-associated will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4168109